Supernus Pharmaceuticals, a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, has received the Food and Drug Administration’s blessing for an expanded indication of Qelbree (viloxazine extended-release capsules) for the treatment of attention deficit hyperactivity disorder in adult patients aged 18 years old and older.
Qelbree is now approved for the treatment of ADHD in children, starting at age 6 years old, adolescents and adults.
“Until today, nonstimulant ADHD options for adults have been very limited,” said Greg Mattingly, founding partner of St. Charles Psychiatric Associates in St. Louis. “This approval is positive news and offers a new novel option for the millions of American adults who are trying to find the right treatment to manage their ADHD symptoms.”
Approximately 16 million children, adolescents and adults have ADHD in the United States. While many children with ADHD outgrow it, up to 90% of those diagnosed with ADHD in childhood continue to have ADHD as adults, the company noted.
“As a leader in the field of CNS, we are fully committed to better understanding how to treat complex diseases such as ADHD,” said Jack Khattar, president and CEO of Supernus Pharmaceuticals.
“Today’s approval marks a major advancement in the treatment of ADHD and is an important milestone just one year after the approval of Qelbree to treat pediatric patients,” Khattar said. We are proud to bring a new novel nonstimulant option for adults into the market after two decades.”
Sally Hansen throws it back to the ’90s with ‘Friends’ collection
Sally Hansen is pivoting back to the ’90s with a collection of nail polishes inspired by the classic TV series “Friends.”
The beauty brand is rolling out 10 new shades of its Miracle Gel line that were influenced by iconic moments on the show.
Featuring a chip-resistant and long-lasting formula that can keep a fresh manicure for up to eight days, the “Friends” collection is designed to help consumers channel their inner Rachel, Monica, Phoebe, Ross, Joey and Chandler, the company said.
The collection features the following hues: Oh. My. Coffee, Central Pink, A Moo Point, Lavendoor, Yellow Taxi, Stick To The Routine, The One With The Teal, How You Bluein’?, Pivot and He’s Her Lobster.
Retailing for $9.99 each, Sally Hansen’s “Friends” collection is available at mass market, drug store, food and e-commerce retailers nationwide.
The Consumer Healthcare Products Association is welcoming Logan Tucker as director of communications and media relations.
In this role, Tucker will serve as the primary contact for directing CHPA’s media strategies and tactics, and coordinate with other communications department staff to manage news, events and issues in the consumer healthcare industry. She will report to Anita Brikman, the organization’s senior vice president of communications and public affairs.
“CHPA is thrilled to welcome Logan to our staff,” said Brikman. “With more than a decade of combined legislative, communications and consulting experience, Logan’s professional background will certainly add value to our association’s communications department while enhancing our ability to amplify the impact of CHPA’s initiatives.”
Tucker joins CHPA from Deloitte, where she was a senior consultant in the firm’s government and public services sector, serving clients at both the federal and state levels. Prior to Deloitte, Tucker spent nearly 10 years on Capitol Hill, where she served in numerous communications roles, including as deputy chief of staff and communications director for Congressman Mark Amodei of Nevada.
“I’m honored to join the CHPA team, and additionally grateful for the opportunity to highlight the important work our member companies do each day to ensure American consumers are able to pursue happier and healthier lives through responsible self-care,” Tucker said.
She also previously served as communications director for Congressman Stephen Fincher of Tennessee and as a press assistant for Wyoming Senator John Barrasso. Tucker is an Austin, Texas native who has a bachelor’s degree in public relations from Texas Tech University.
Advanz Pharma, a pharmaceutical company with a strategic focus on specialty pharmaceuticals, specialty and hospital generics in Europe, is welcoming Steffen Wagner as its new CEO.
Wagner joins from Stada, where he was a member of the Global Executive Committee and responsible for European markets. A medical doctor by training, he has previously held senior roles at Biogen and within the Novartis Group, and worked as a consultant at McKinsey and Bain.
In addition, Wagner brings extensive international pharma experience that will be highly valuable in driving Advanz Pharma’s continued journey to be the partner of choice for commercializing specialty pharmaceuticals, specialty and hospital generics in Europe, the company said.
Wanger was appointed together with several other recent senior leadership hires as Advanz Pharma now enters into the next phase of its growth journey. These appointments include new CFO Andreas Stickler, who joined from Merck KGaA, and Susanna El-Armale, who joined as chief corporate development officer from Theramex.
“This is a hugely exciting time to be joining Advanz Pharma. It is a great platform on which we can build to achieve our vision to be a partner of choice in specialty pharmaceuticals in Europe,” Wagner said. “We will further expand the commercial footprint and accelerate growth via mergers and acquisitions, business development and licensing, and product launches. I am looking forward to working with my Advanz Pharma colleagues and helping to improve patients’ lives by providing the critical medicines they depend on.”
Lundbeck names CFO, head of corporate functions
Lundbeck is welcoming a new executive. Joerg Hornstein is joining as chief financial officer and member of Lundbeck’s executive management. He will assume the role no later than Sept. 1, 2022, and he will be registered with the Danish Business Authority.
Lundbeck described Hornstein as an action-oriented, change-driven leader, with a strong track record in integrating, restructuring, scaling up and improving business performance and productivity in pharmaceutical, biotech and fast-moving consumer goods industries. He has proven experience in executive management roles and as a principal financial advisor on boards of directors.
Hornstein is joining Lundbeck from AC Immune, a clinical-stage biopharmaceutical company specialized in precision medicine to diagnose, treat and prevent neurodegenerative diseases, headquartered in Lausanne, Switzerland, where he currently serves as executive vice president and chief financial officer.
“Following a thorough internal and external search, we are delighted to welcome Joerg to Lundbeck. He brings extensive experience in delivering results and creating value across increasingly complex financial roles in Merck KGaA, Unternehmensgruppe Theo Mueller and, most recently, as CFO of AC Immune,” said Deborah Dunsire, CEO of Lundbeck.
“Joerg has a strong mix of understanding of neuroscience and pharma, exceptional operational experience across multiple functions and countries, and demonstrated ability to lead through business transformations. The insights he has gained by leading across cultures and through periods of significant change will be valuable in ensuring Lundbeck continues to be well positioned for sustainable, long-term value creation in the years ahead,” Dunsire said.
Hornstein has been with AC Immune since 2017, where he oversaw finance and various corporate functions. Over the years, he led a financial transformation of the company’s operations, leading to a strengthened financial and investor position. He also implemented state of the art systems and processes across all corporate functions, as well as a new portfolio investment approach.
Prior to AC Immune, he served as senior vice president and head of group controlling at Unternehmensgruppe Theo Mueller, a consumer products company with operations across the entire value chain and an annual revenue of approximately 7 billion euros. In this role, Hornstein transformed the financial profile of the business during periods of major acquisitions and significant organic growth.
He began his career at Merck KGaA, where he spent 12 years in financial roles of increasing responsibility across different businesses, including roles at the headquarters in Germany, as well as in Indonesia, China and the United States. Hornstein has lived in six countries and is a German national.